ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Geriatric Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,259Medicare Part D Prescriptions Filled, Including Refills

Rank: 12 out of 54

$502K Total Retail Price of All Prescriptions

Rank: 13 out of 54

167 Patients Receiving at Least One Drug in Part D
86%Patients 65 Years and Older
96% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Connecticut
Lower avg

Schedule Two
Controlled Substances

14% of this provider’s 167 patients filled at least one prescription for a schedule two drug, compared to an average of 8%.

Schedule Three
Controlled Substances

18% of this provider’s 167 patients filled at least one prescription for a schedule three drug, compared to an average of 3%.

Risky Drugs to Seniors

1% of this provider’s 6,991 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$61 was the average price of a prescription from this provider, compared to $59 among peers.

Prescriptions per Patient

49 is the average number of prescriptions (including refills) per patient, compared to an average of 26.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Connecticut
METOPROLOL SUCCINATE 289 241 1 14
FAMOTIDINE 287 239 2 55
LISINOPRIL 275 229 3 6
SIMVASTATIN 246 206 4 5
LEVOTHYROXINE SODIUM 216 190 5 2
ATORVASTATIN CALCIUM 212 183 6 15
METOPROLOL TARTRATE 194 154 7 7
HYDRALAZINE HCL 184 181 8 58
DONEPEZIL HCL 177 177 9 8
HYDROCODONE-ACETAMINOPHEN 171 162 S3 10 39
AMLODIPINE BESYLATE 170 146 11 4
POLYETHYLENE GLYCOL 3350 156 137 12 37
GABAPENTIN 145 110 13 16
OMEPRAZOLE 143 143 14 9
CYMBALTA 141 92 15 26
FUROSEMIDE 130 130 16 3
TRAZODONE HCL 120 94 17 10
MIRTAZAPINE 116 116 18 11
NAMENDA 114 114 19 13
ESCITALOPRAM OXALATE 112 112 20 18
ISOSORBIDE MONONITRATE ER 111 102 21 41
QUETIAPINE FUMARATE 107 103 22 21
HYDROCHLOROTHIAZIDE 99 91 23 20
TAMSULOSIN HCL 97 75 24 25
SERTRALINE HCL 85 82 25 12
DIOVAN 77 64 26 29
FENTANYL 75 64 S2 27 92
LANTUS 75 75 27 30
ALENDRONATE SODIUM 70 58 29 31
JANUVIA 67 48 30 85
METFORMIN HCL ER 65 48 31 82
FINASTERIDE 62 51 32 73
ACTOS 61 43 33 154
WARFARIN SODIUM 58 58 34 1
EXELON 57 57 35 63
FLUOXETINE HCL 57 43 35 67
CLOPIDOGREL 57 57 35 38
CLOTRIMAZOLE-BETAMETHASONE 56 46 38 85
OXYCODONE-ACETAMINOPHEN 55 37 S2 39 98
PRAVASTATIN SODIUM 54 46 40 27
ABILIFY 52 47 41 80
PROAIR HFA 51 51 42 103
BUSPIRONE HCL 51 51 42 179
SPIRONOLACTONE 51 51 42 63
LEVETIRACETAM 50 27 45 46
NYSTATIN-TRIAMCINOLONE 50 49 45 182
LOSARTAN POTASSIUM 50 41 45 48
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.